Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTIVENESS OF VENLAFAXINE IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSION AND MELANCHOLIA
Autore:
GUELFI JD; WHITE C; HACKETT D; GUICHOUX JY; MAGNI G;
Indirizzi:
CLIN MALAD MENTALES & ENCEPHALE,DEPT PSYCHIAT,100 RUE SANTE F-75674 PARIS 14 FRANCE WYETH AYERST CLIN RES & DEV EUROPE,DEPT BIOSTAT SLOUGH BERKS ENGLAND WYETH AYERST CLIN RES & DEV EUROPE,DEPT CNS PARIS FRANCE UNIV PADUA,SCH MED PADUA ITALY
Titolo Testata:
The Journal of clinical psychiatry
fascicolo: 10, volume: 56, anno: 1995,
pagine: 450 - 458
SICI:
0160-6689(1995)56:10<450:EOVIPH>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
TRUE DRUG RESPONSE; PATTERN-ANALYSIS; DESIPRAMINE; FLUOXETINE; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
J.D. Guelfi et al., "EFFECTIVENESS OF VENLAFAXINE IN PATIENTS HOSPITALIZED FOR MAJOR DEPRESSION AND MELANCHOLIA", The Journal of clinical psychiatry, 56(10), 1995, pp. 450-458

Abstract

Background: This study was undertaken to compare the antidepressant efficacy and shortterm safety of venlafaxine with those of placebo in hospitalized patients with major depression and melancholia. Method: Ninety-three inpatients with a minimum prestudy Montgomery-Asberg Depression Rating Scale (MADRS) score of 25 were treated for up to 4 weeks with either venlafaxine or placebo. Dosage averaged approximately 350 mg/day during Weeks 2 to 4. Efficacy and safety were assessed throughout the study. Efficacy was evaluated using the MADRS, the 21-item Hamilton Rating Scale for Depression (HAM-D), and the Clinical Global Impressions (CGI) scale. Recorded study events, vital signs and body weightmeasurements, laboratory determinations, physical examinations, and ECG recordings were used to assess safety. Results: Venlafaxine provided significantly greater improvement in the MADRS scores after 4 days and in the HAM-D scores after I week than did placebo. Response rate (based on a 50% decrease in MADRS scores) was 65% (30 of 46 patients) for venlafaxine and 28% (13 of 47 patients) for placebo. Significantly more placebo-treated patients (40%; N = 19) than venlafaxine-treated patients (9%; N = 4) discontinued treatment early because of lack of efficacy. Nausea and sweating were the most common events, occurring at asignificantly higher rate in the venlafaxine group. Conclusion: Venlafaxine is an effective and well-tolerated antidepressant in hospitalized patients with major depression and melancholia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 07:28:47